	US 12,466,873 B2
	Modified anti-inflammatory proteins and method of use
Alex Loukas, Townsville (AU); Andrew Leech, Townsville (AU); and Darren Pickering, Townsville (AU)
Assigned to James Cook University, Townsville (AU)
Filed by James Cook University, Townsville (AU)
Filed on Jan. 16, 2024, as Appl. No. 18/414,112.
Application 18/414,112 is a continuation of application No. 17/071,563, filed on Oct. 15, 2020, granted, now 11,976,108.
Application 17/071,563 is a continuation of application No. 15/023,165, granted, now 10,822,395, issued on Nov. 3, 2020, previously published as PCT/AU2014/050240, filed on Sep. 18, 2014.
Claims priority of application No. 2013903588 (AU), filed on Sep. 18, 2013.
Prior Publication US 2024/0400649 A1, Dec. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/81 (2006.01); A61K 38/00 (2006.01); A61K 38/57 (2006.01); A61K 45/06 (2006.01); C07K 14/435 (2006.01)

CPC C07K 14/81 (2013.01) [A61K 38/57 (2013.01); A61K 45/06 (2013.01); C07K 14/4354 (2013.01); C07K 14/8146 (2013.01); A61K 38/00 (2013.01)]

15 Claims

1. A modified Ac-TMP-2 protein which lacks one or a plurality of C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein, or a fragment or derivative thereof of the modified Ac-TMP-2 protein, wherein the modified Ac-TMP-2 protein comprises:

the amino acid sequence set forth in SEQ ID NO: 5, or an amino acid sequence having at least 95% sequence identity thereto;

a signal peptide amino acid sequence;

a heterologous C-terminal amino acid sequence; and

wherein the modified Ac-TMP-2 protein is capable of preventing, reducing and/or alleviating inflammation upon administration to a subject.